Results 31 to 40 of about 1,849,608 (371)

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. [PDF]

PLoS Pathogens, 2017
Human cytomegalovirus (HCMV) is an important, ubiquitous pathogen that causes severe clinical disease in immunocompromised individuals, such as organ transplant recipients and infants infected in utero.
Anna Bootz, Astrid Karbach, Johannes Spindler, Barbara Kropff, Nina Reuter, Heinrich Sticht, Thomas H Winkler, William J Britt, Michael Mach   +8 more
doaj   +1 more source

Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19

Human Vaccines & Immunotherapeutics, 2023
This post-hoc analysis compared the receptor-binding domain (RBD)-specific and pseudovirus neutralizing antibodies against the wild-type SARS-CoV-2 strain elicited by one or two doses (56-d interval) of Ad5-nCoV vaccine regimen (NCT04341389 and ...
Jia-Lu Feng, Wen-Juan Wang, Peng-Fei Jin, Hui Zheng, Lai-Run Jin, Xin Xia, Xiao-Yin Zhang, Zhuo-Pei Li, Jing-Xin Li, Feng-Cai Zhu   +9 more
doaj   +1 more source

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Science, 2020
Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al.
P. Brouwer, Tom G. Caniels, K. van der Straten, Jonne L. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, Nisreen M. A. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. M. van Haaren, Denise Guerra, J. Burger, Edith E. Schermer, K. Verheul, N. van der Velde, Alex van der Kooi, J. van Schooten, M. V. van Breemen, Tom P. L. Bijl, Kwinten Sliepen, A. Aartse, R. Derking, I. Bontjer, N. Kootstra, W. Wiersinga, G. Vidarsson, B. Haagmans, A. Ward, G. D. de Bree, R. Sanders, M. V. van Gils   +32 more
semanticscholar   +1 more source

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Science, 2020
SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al.
A. Wajnberg, F. Amanat, A. Firpo, D. Altman, M. Bailey, M. Mansour, Meagan McMahon, Philip Meade, D. R. Mendu, K. Muellers, D. Stadlbauer, K. Stone, Shirin Strohmeier, V. Simon, J. Aberg, D. Reich, F. Krammer, C. Cordon-Cardo   +17 more
semanticscholar   +1 more source

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Science, 2020
An antibody defense against COVID-19 One of the responses of the immune system to invading viruses is the production of antibodies. Some of these are neutralizing, meaning that they prevent the virus from being infectious, and can thus be used to treat ...
Yan Wu, Feiran Wang, Chenguang Shen, Weiyu Peng, Delin Li, Cheng Zhao, Z. Li, Shihua Li, Y. Bi, Yang Yang, Y. Gong, Haixia Xiao, Z. Fan, Shuguang Tan, Guizhen Wu, W. Tan, Xuancheng Lu, Changfa Fan, Qihui Wang, Yingxia Liu, Chen Zhang, J. Qi, G. Gao, F. Gao, Lei Liu   +24 more
semanticscholar   +1 more source

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

bioRxiv, 2020
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2.
Y. Weisblum, F. Schmidt, Fengwen Zhang, Justin DaSilva, D. Poston, Julio C. C. Lorenzi, F. Muecksch, Magda Rutkowska, Hans-Heinrich Hoffmann, E. Michailidis, C. Gaebler, Marianna Agudelo, A. Cho, Zijun Wang, A. Gazumyan, M. Cipolla, Larry L. Luchsinger, C. Hillyer, M. Caskey, D. Robbiani, C. Rice, M. Nussenzweig, T. Hatziioannou, P. Bieniasz   +23 more
semanticscholar   +1 more source

Identification of a conserved neutralizing epitope in Seneca Valley virus VP2 protein: new insight for epitope vaccine designment

Virology Journal, 2022
Background Seneca Valley virus (SVV) is a picornavirus that causes vesicular disease in swine. Clinical characteristics of the disease are similar to common viral diseases such as foot-and-mouth disease virus, porcine vesicular disease virus, and ...
Wei Wen, Xinghua Chen, Qiang Lv, Huanchun Chen, Ping Qian, Xiangmin Li   +5 more
doaj   +1 more source

A sensitive and reproducible cell-based assay via secNanoLuc to detect neutralizing antibody against adeno-associated virus vector capsid

Molecular Therapy: Methods & Clinical Development, 2021
Most gene therapy clinical trials that systemically administered adeno-associated virus (AAV) vector enrolled only patients without anti-AAV-neutralizing antibodies.
Nemekhbayar Baatartsogt, Yuji Kashiwakura, Morisada Hayakawa, Nobuhiko Kamoshita, Takafumi Hiramoto, Hiroaki Mizukami, Tsukasa Ohmori   +6 more
doaj  

Neutralizing Antibodies against SARS-CoV2

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2023
Coronavirus disease 2019 (COVID-19) is an illness due to a novel coronavirus which is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Though this virus is recently identified in 2019, it is closely related to other coronaviruses namely SARS-
Prachi Athavale, Virendra Athavale, Poonam Suryawanshi, Kishor Khillare, Srikanth Tripathy   +4 more
doaj   +1 more source

COVID-19 neutralizing antibodies predict disease severity and survival

medRxiv, 2020
COVID-19 exhibits variable symptom severity ranging from asymptomatic to life-threatening, yet the relationship between severity and the humoral immune response is poorly understood.
W. García-Beltrán, E. Lam, M. Astudillo, Diane Yang, T. Miller, J. Feldman, B. Hauser, T. Caradonna, K. Clayton, Adam D Nitido, M. Murali, G. Alter, R. Charles, A. Dighe, J. Branda, J. Lennerz, D. Lingwood, A. Schmidt, A. Iafrate, A. Balazs   +19 more
semanticscholar   +2 more sources